Tumor necrosis factor is essential in triggering healing mechanisms but can initiate both cell death or survival pathways depending on the pathophysiological conditions. It is produced under two biologically active forms, a soluble one (solTNF) resulting from the regulated cleavage of the extracellular domain of the transmembrane form (tmTNF). SolTNF signals specifically through the ubiquitously expressed receptor TNFR1, while tmTNF is able to bind both TNFR1 and TNFR2. 2 Unlike TNFR1, TNFR2 is expressed by a restricted number of cells (immune cells, endothelial cells, as well as neurons, astrocytes, and oligodendrocytes in the central nervous system (CNS)) and lacks a death domain, therefore triggering mostly prosurvival pathways by activating phosphoinositide-3 kinase (PI3K)
and NF-κB. 3, 4 Although the inhibition of TNF (both soluble and transmembrane forms) in clinical trials, aimed at treating patients suffering from multiple sclerosis, surprisingly exacerbated the disease, 5, 6 there are many examples of favorable outcomes when only the signals elicited by solTNF are inhibited while TNFR2 signaling is maintained, demonstrating the beneficial effects of tmTNF in CNS pathologies. Studies in experimental autoimmune encephalomyelitis (EAE), a murine model of MS, describe a more severe pathology in animals lacking TNFR2 expression. 7 Moreover, selective inhibition of solTNF results in an improved clinical outcome, whereas inhibitors blocking all TNF signaling did not have any noticeable effect on the disease course. 8 TNFR2 activity also promotes remyelination and oligodendrocyte precursor cells (OPCs) proliferation after cuprizone-induced demyelination, 9 the proliferation of OPCs being mediated by CXCL12 released from activated astrocytes through TNFR2 signaling. 10 TNFR2 can also protect OPCs from oxidative stress.
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In vitro studies have shed some light on the protective effects and mechanisms mediated by TNFR2: Inhibition of TNFR2 in neuronal cells enhanced the susceptibility of these cells to hypoxic insults or beta-amyloid toxicity, 12 whereas oligodendrocytes matured in response to leukemia inhibitory factor (LIF) secreted by astrocytes in response to TNFR2 stimulation. 13 In the case of spinal cord injury, solTNF is upregulated and contributes to apoptosis, 14 an increased trafficking of AMPA receptors at the plasma membrane triggered by TNF exacerbating the process. 15 The lack of either both TNF forms 16 or solTNF only 17 does not provide any protection or improvement following injury;
however, short-term inhibition of solTNF (3 days) signaling is beneficial. 18 After having reported a decreased expression of TNFR2 in the latter study after spinal cord injury and having observed effects of TNFR2 signaling in neurons and OPCs in vitro that one might consider beneficial after a traumatic insult to the cord, we wondered whether enhancing TNFR2 signaling activity through stimulation with a specific agonist might enhance recovery. Our data show that in vitro TNFR2 stimulation protects neurons against glutamate-induced cytotoxicity. In vivo, following spinal cord injury, stimulation of TNFR2 helps improving locomotion, as well as remodeling neuronal circuitry.
| MATERIAL S AND ME THODS

| Cell culture
The EHD2-sc-mTNF R2 agonist was described previously. 19 
| Cell death assay
Neurons were pretreated with the TNFR2-specific agonist EHD2-sc- 
| Mice and spinal cord injury
All animal experiments followed NIH and Drexel University IACUC guidelines for the use of laboratory animals.
Adult female C57Bl/6 mice (3 months old) were purchased from Jackson Laboratory and were acclimated for at least 1 week before undergoing surgery as previously described. 18 Briefly, following anesthesia with ketamine (100 mg/kg) and xylazine (10 mg/ kg), a laminectomy was performed at thoracic level T9 and the exposed spinal cord was contused using the Infinite Horizon impactor (Precision Systems and Instrumentation, LLC) with a desired force of 65 kDynes. Following injury, muscles of the back, as well as the skin, were sutured. After injury, lactated Ringer's solution was administered subcutaneously twice daily for at least 7 days to prevent dehydration, buprenorphine (0.1 mg/kg) twice a day for 2 days for pain relief and gentamicin (80 mg/kg) once a day for 7 days as a preventive measure against bladder infection. Bladders were expressed twice daily until normal function was recovered. Data related to the injuries are reported in Table S1 .
| Drug administration
Micro-osmotic pumps connected to brain infusion kits III (ALZET), affixed to the vertebrae with the cannula placed above the lesion immediately following injury, were used to deliver EHD2-sc-mTNF R2 .
The concentrations were adjusted according to the experiment conducted to maintain daily delivery of similar amounts: 10 mg/mL for 
| Electrophysiology and locomotion behavior
The animals' locomotion during the recovery period was assessed using the BMS scoring system developed by Basso et al. 20 The animals were tested at day 1 after injury (the animals not displaying paralysis were excluded from the study) and then once a week for six consecutive weeks.
| Electrophysiology
Two weeks after injury, animals were anesthetized with 1. 
| Peripheral electrical stimulation
Bipolar stimulating electrodes were inserted subcutaneously into the ankle of the hindlimb contralateral to the recording site ( Figure   S1A ). For each animal, electrical stimulation, consisting of 100 pulses at 0.5 Hz with a 1.0 ms pulse duration at 1.0 mA of current, was applied as the neural response was recorded.
| Evoked responses
Local To ensure that we were accurately placing the recording sites at the proper depth, current source density analysis was used to confirm electrode placement. In naïve animals, CSD profiles of responses to hindlimb stimulation were obtained. The strongest current sink in the naïve animals corresponded to a depth of 500 microns and was estimated to be the granular layer ( Figure S1B ,C).
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| Spinal cord tissue analysis
Measurement of lesion volume and immunohistochemistry: The animals were perfused transcardially with phosphate-buffered saline followed by ice-cold 4% paraformaldehyde (PFA). The tissue was postfixed for 4 hours in PFA before transfer to 25% sucrose overnight. The cords were embedded and frozen in OCT (Tissue-Tek) before sectioning with a cryostat. Thirty micrometre transversal sections were stained using rabbit anti-GFAP antibodies (1:1000, DAKO) to identify the edge of the lesion. Four sections 300 µm apart were used, and the volume of the lesion was estimated using the Stereology Module of Slidebook6 software. TUNEL staining was performed to identify cell death using the ApopTag staining kit (EMD Millipore). were resolved on SDS-PAGE gels before being transferred onto nitrocellulose membranes using the Trans-Blot ® Turbo™ system (Bio-Rad). Antibodies for the Western blot detection included rabbit anti-CNPase (1:5000; Cell signaling), mouse anti-NF200
| Protein expression and RNA analysis
(1:5000; Sigma), rabbit anti-PI3Kγ (1:500; Santa Cruz), and mouse anti-β-tubulin (1:60 000; Sigma).
RNAs were extracted using TRIzol (Thermo Fisher) following the manufacturer's instructions. RT-PCR was performed with the Omniscript RT kit (Qiagen) followed by qPCRs performed using the Rotor-Gene SYBR ® Green PCR Kit, and the Rotor-Gene Q real-time PCR cycler (Qiagen). Each gene expression levels were determined using a standard curve for that gene, and the data were normalized to β-actin expression levels. The primers used are listed in the Table S2 .
| Statistical analysis
Comparisons between groups were performed using one-way analysis of variance (ANOVA) followed by post hoc Tukey's test. If only two groups, a two-tailed t test was used.
F I G U R E 1 Effect of TNFR2 activation on glutamate-induced neuronal cell death. A, Timeline of the experiment. B, Effect of pretreatment with EHD2-sc-mTNF R2 on glutamate-induced neuronal cell death. Cells were pretreated for 12 h, 24 h, or 48 h prior to addition of 300 μmol/L of glutamate. C, Effect of treatment with EHD2-sc-mTNF R2 at time (0h) or 6 h prior the addition of glutamate on cell death. D, Role of PI3Kγ in the protection provided by EHD2-sc-mTNF R2 on glutamateinduced neuronal cell death. Cells were pretreated for 6 h with EHD2-sc-mTNF R2 alone or in combination with either A66 (PI3K/p110α inhibitor) or AS 605240 (PI3K/p110γ inhibitor). E, Role of p38 MAPK in glutamate-induced cell death. Cells were pretreated for 4 h with either EHD2-sc-mTNF R2 alone or with SB203580 (p38 inhibitor). All bar graphs represent the mean ± SEM of eight separate samples for each condition. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 (compared to untreated controls). ººººP < 0.0001; ºººP < 0.001; ººP < 0.01; ºP < 0.05 (compared to glutamate controls). +P < 0.05, ++++P < 0.0001 (compared to glutamate/EHD2-scmTNF R2 )
| Behavior
A two-way ANOVA was performed.
| Electrophysiology
The proportion of responses was compared across groups for each layer separately using the chi-squared test with the Fisher's exact test post hoc. Changes in SEP amplitude and latency were not normally distributed. Kruskal-Wallis test was used to evaluate statistical differences in SEP amplitude and latency between groups, separately for each layer. Post hoc Mann-Whitney U test assessed differences between PBS controls and treated animals if the Kruskal-Wallis was significant. All results were considered statistically significant at P < 0.05.
| RE SULTS
| Activation of TNFR2 protects neurons against glutamate-induced cell death
Given the body of evidence describing the neuroprotective role of TNFR2, we studied how neurons would respond to stimulation with a specific agonist for this receptor. A previous study demonstrated a protective effect against glutamate excitotoxicity after antibody-mediated pre-activation of TNFR2 through the activation of PI3 kinase. 25 We reexamined these experiments with the specific agonist EHD2-sc-mTNF R2 ( Figure 1A) . A short pretreatment (6 hours) with TNFR2 agonist before treatment with glutamate decreased noticeably the amount of cells dying compared to cells pretreated for a longer time (12, 24 or 48 hours) ( Figure 1B, C) . Interestingly, stimulation of TNFR2 performed simultaneously with exposure to glutamate was also able to prevent the neurons from dying as effectively as a treatment with the agonist initiated 6 hours earlier ( Figure 1C) . Using inhibitors targeting different classes of PI3K catalytic subunits, we observed that p110γ was the protein mediating the signal provided by TNFR2 activation (Figure 1D ), as treatment with AS605240 abrogated the protective effect elicited by EHD2-sc-mTNF R2 . A similar experiment using the p110α inhibitor A66 did not block the protective effect triggered by TNFR2 stimulation. We then examined the potential involvement of p38 MAPK on the pathway activated by EHD2-sc-mTNF R2 as this kinase has been implicated in PI3Kγ signaling 26 and observed that its inhibition abolished the protection from glutamate excitotoxicity provided by activation of TNFR2 ( Figure 1E ).
| Effect of EHD2-sc-mTNF R2 on recovery following spinal cord injury
Since activating TNFR2 with a specific agonist can have effects on two cell types (neurons and oligodendrocytes) that would be con- or proteolipid protein (PLP), did not appear to be affected by our treatment. We also did not observe any changes in the expression of glial fibrillary acidic protein (GFAP) or Iba-1, a marker of activated microglia (not shown). Interestingly, although we identified PI3Kγ as a mediator of the neuroprotection pathway activated by TNFR2, the levels of that protein were significantly lower after treatment with the TNFR2 agonist 6 weeks following the contusion compared to PBS treatment ( Figure 3B ).
| TNFR2 activation does not modulate cytokine expression in the acute phase
TNFR2 stimulation has been associated with a decrease in immunological response in some models, which led us to consider whether the modulation of early inflammatory signaling could be affected by the TNFR2 agonist. The levels of some gene transcripts involved in inflammatory pathways were analyzed 6h and 1d after contusion in F I G U R E 3 Expression levels of proteins around the lesion site following spinal cord injury. A, Expression of CNPase, neurofilament H (NF200), and PI3Kγ 2 weeks following injury. Bar graphs represent the mean ± SEM of n = 3 naïve (N), n = 4 PBS, and n = 6 R2A. ***P < 0.001; **P < 0.01; *P < 0.05. B, CNPase, NF200, and PI3Kγ protein expression, 6 weeks following injury. Last sample in the NF200 blot was an outlier as determined by the Grubb's method and was excluded from the bar graph. Bar graphs represent the mean ± SEM of n = 3 naïve, n = 6 PBS, and n = 5 R2A ***P < 0.001; **P < 0.01; *P < 0.05. PBS: spinal cord injured controls infused with PBS; R2A: spinal cord injured animals infused with EHD2-sc-mTNF R2
the spinal cord, but we did not observe any significant changes triggered by TNFR2 agonist in the levels of TNF, IL-1β, IL-33, CCL2, and CXCL10 compared to PBS (Figure 4 ).
| Enhanced cortical response activation after spinal cord injury following TNFR2
Finally, a mounting body of evidence points to axon sprouting and cortical reorganization that can contribute to the recovery following spinal cord injury, even in the case of a complete transection. 27 To determine whether the effect of the TNFR2 agonist could affect the cortical response to sensory stimuli, the response to hindlimb stimulation was compared across groups. As expected, the in- 
| D ISCUSS I ON
We report observing several potentially beneficial effects promoted by the specific activation of TNFR2 following spinal cord injury that could contribute to a positive effect on the recovery process. The infusion of the agonist EHD2-sc-mTNF R2 over a month after contusive thoracic spinal cord injury allowed the animals to exhibit better locomotion as assessed with the BMS test.
Early activation of TNFR2 did not reduce inflammation, as could have been suspected from recent work demonstrating that the activation of that receptor in microglia curbs the inflammatory response in experimental autoimmune encephalomyelitis. 28 TNFR2
activation may also have a direct protective effect on neurons in the cord as it is able to preserve them in vitro from an exposure to excessive glutamate concentrations, which are known to increase following spinal cord injury and cause excitotoxic cell death. 29, 30 We present evidence here that the activation of TNFR2 does not F I G U R E 4 Acute response of genes linked to the inflammatory response after spinal cord injury. The RNA levels were measured 6 h and 1 d after injury by quantitative real-time PCR. Data for each gene were normalized to β-actin and expressed as a percentage of the naïve uninjured control. Bar graphs represent the mean ± SEM of n = 3/group/time point *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 need to precede the glutamate insult as previously thought, 25 but rather that it can occur simultaneously and that it is mediated by PI3Kγ. We observed a noticeably stronger protective effect with shorter times between TNFR2 stimulation and glutamate exposure (0 or 6 hours, compared to 12 hours and up), suggesting that the signaling may be downregulated to levels inadequate to provide complete protection from glutamate excitotoxicity if TNFR2 gets activated too early. Surprisingly, while PI3Kγ was increased at 2 weeks after injury, there was no difference between EHD2-scmTNFR2 and PBS treated groups. Furthermore, the levels of PI3Kγ
were significantly lower at 6 weeks in the group treated with the TNFR2 agonist compared to PBS. However, any neuroprotective effect mediated by PI3Kγ would most likely occur early after injury, within hours or a few days at most. Besides its protective effect from glutamate-induced excitotoxicity, PI3Kγ contributes to neuroinflammation, 31 and a decreased expression because of activation of TNFR2 could prevent inflammation to be sustained at levels that could prove harmful over long periods of time. Despite the positive effects observed in vitro on neurons in our study and 
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